New guidelines for treatment and prevention of HIV infection in adults

July 24, 2018

The International Antiviral Society-USA Panel has released updated recommendations for the treatment and prevention of HIV infection in adults, published in the Journal of the American Medical Association. Michael Saag, M.D., director of the University of Alabama at Birmingham's Center for AIDS Research, served as the article's lead author.

The recommendations, developed by a volunteer panel of international experts in HIV research and patient care, outline new findings, drugs, approaches and data as updates to previous recommendations from 2016. They are intended to be used as guidelines by clinicians moving forward.

The recommendations indicate that continued advances in the development of antiretroviral drugs for HIV prevention and treatment are necessary and are contributing to improved clinical management and outcomes for individuals at risk for or living with HIV.

"The recommendations reflect the joint commitment of researchers working to collectively improve clinical outcomes and treatments available for all at-risk or infected HIV patients," said Saag, professor of medicine in UAB's Division of Infectious Diseases. "We know that antiretroviral therapy is the cornerstone of prevention and management of HIV infection; but it's critical to continually evaluate new data and treatments for initiating therapy, monitoring individuals starting therapy, changing regimens and preventing HIV infection for those at risk, reaffirming the standard of providing the utmost treatment and care possible."

In addition to reconfirming 2016 recommendations of antiretroviral therapy (ART) as a substantial means for HIV treatment and prevention, updated recommendations include but are not limited to:An alternative for pre-exposure prophylaxis for those who are uninfected with HIV but remain at risk for infection to now include an episode-based approach where individuals can take preventive ART pills prior to exposure, and a follow-up pill once daily for two days post-exposure

"HIV care continues to evolve, and clinicians and their patients benefit from applying the latest knowledge to keep pace with the many ways this has changed," said Paul Volberding, M.D., professor at the University of California San Francisco and a study co-author. "The latest IAS-USA guidelines continue a tradition of providing a concise and current set of recommendations, and we are proud of how these have captured the directions in our field of medicine."

According to the article, all updated recommendations focus on adults 18 years or older with or at risk for HIV infection with availability to most antiretroviral drugs.
-end-
In addition to Saag and Volberding, panel members included Constance A. Benson, M.D., University of California San Diego School of Medicine; Rajesh T. Gandhi, M.D., Massachusetts General Hospital; Jennifer F. Hoy MBBS, The Alfred Hospital and Monash University; Raphael J. Landovitz, M.D., University of California Los Angeles; Michael J. Mugavero, M.D., MHSc, University of Alabama at Birmingham; Paul E. Sax, M.D., Brigham and Women's Hospital; Davey M. Smith, M.D., University of California Los Angeles, La Jolla; Melanie A. Thompson, M.D., AIDS Research Consortium of Atlanta; Susan P. Buchbinder, M.D., San Francisco Department of Public Health and University of California San Francisco; Carlos del Rio, M.D., Emory University Rollins School of Public Health and School of Medicine; Joseph J. Eron Jr., M.D., University of North Carolina Chapel Hill School of Medicine; Gerd Fåtkenheuer, M.D., University Hospital of Cologne; Huldrych F. Günthard, M.D., University Hospital Zurich and Institute of Medical Virology; Jean-Michel Molina, M.D., University of Paris Diderot and Saint-Louis Hospital; and Donna M. Jacobsen, B.S., International Antiviral Society-USA.

For a complete look at the recommendations and further details, visit the Journal of the American Medical Association.

University of Alabama at Birmingham

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.